6 August 2021

Non-insulin injectables for T2D

Clinical Diabetes

Dr David Lim and Associate Professor Neale Cohen discuss why GPs should consider GLP1 agonists as a management option.

To read the rest of this article you need to be a Medical Republic Member and registered with AHPRA, Please login below if you have an account or sign up to join.

Join Now / Login